An observational study in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-05-06.
Sponsored by Boehringer Ingelheim · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 17th largest by enrollment of the 34 observational ones that give a count, is one of 4 that started in 2017, is one of 34 observational ones, and was the 106th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Australia, Canada and 3 more countries
Ages 18+
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 48 more countries
Ages 18+
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11,001 is above the median of 300 across 1,742 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 302 across the 96 interventional studies, 10,286 across the 34 observational. Of the 125 that completed or were terminated, 109 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,304 studies on the registry; 61 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05882071Boehringer IngelheimNon-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A non-interventional cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data from providers across the United States to determine whether there is comparable effectiveness of linagliptin on glycemic effectiveness
A non-interventional cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data from providers across the United States to determine whether there is comparable effectiveness of linagliptin on glycemic effectivenes
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individual antihyperglycemic medications will be distinguished by generic name using the column labelled "Medication Name" in Tables 2 through 13. Combination products containing two generic ingredients will be considered as two distinct antihyperglycemic medications Note: This exclusion criterion is designed to exclude patients from the study sample if they start a new antihyperglycemic medication other than linagliptin on the index date. Patients that start a new antihyperglycemic medication in the follow-up period will not be removed from the study sample to avoid creating a biased sample. Addition of a new antihyperglycemic medication during follow-up will be evaluated through the sensitivity analysis described in Section 9.7.4.4. While we will be capturing additions of new therapies, discontinuation of linagliptin is not able to be accurately measured in electronic record data. The electronic record data capture prescriptions written by a prescriber, but it is not possible to know if patients received and adhered to their medication and there are no structured data fields to identify if and when a medication was discontinued by the patient or the provider
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Linagliptin
drug
Also known as: ONDERO, TRAJENTA, TRAYENTA, TRAZENTA, TRADJENTA
Change in Glycosylated Hemoglobin (HbA1c) Across Age Categories
Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years). Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date.
Time frame: Baseline and 60 to 180 days
Change in Glycosylated Hemoglobin (HbA1c) Across Renal Function Categories
Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories. Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute/1.73 meter\^2 and eGFR not available).
Time frame: Baseline and 60 to 180 days
Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across the Pre-defined Age Categories
Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years).
Time frame: 60 to 180 days
Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across Renal Function Categories
Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute /1.73 meter\^2 and eGFR not available).
Time frame: 60 to 180 days
Non-interventional, retrospective cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data for the period of 01 July 2011 through 31 March 2017.
| Milestone | Patients With Written Prescription for Initiating Linagliptin |
|---|---|
| Started | 11001 |
| Completed | 11001 |
| Not completed | 0 |
Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years). Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date.
| Percentage (%) | Patients With Written Prescription for Initiating Linagliptin |
|---|---|
| Overall | -0.51 ± 1.46 |
| Age 40 to 54 years | -0.65 ± 1.65 |
| Age 55 to 64 years | -0.59 ± 1.54 |
| Age 65 to 74 years | -0.43 ± 1.36 |
| Age 75+ years | -0.36 ± 1.21 |
Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories. Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute/1.73 meter\^2 and eGFR not available).
| Percentage (%) | Patients With Written Prescription for Initiating Linagliptin |
|---|---|
| Overall | -0.51 ± 1.46 |
| eGFR<30 | -0.22 ± 1.46 |
| eGFR 30 to 44 | -0.33 ± 1.34 |
| eGFR 45 to 59 | -0.47 ± 1.42 |
| eGFR 60 to 89 | -0.55 ± 1.44 |
| eGFR ≥ 90 | -0.70 ± 1.58 |
| eGFR not available | -0.45 ± 1.40 |
Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years).
| Percentage of patients (%) | Patients With Written Prescription for Initiating Linagliptin |
|---|---|
| Overall | 35.72 |
| Age 40 to 54 years | 30.28 |
| Age 55 to 64 years | 35.59 |
| Age 65 to 74 years | 37.89 |
| Age 75+ years | 38.55 |
Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute /1.73 meter\^2 and eGFR not available).
| Percentage of patients (%) | Patients With Written Prescription for Initiating Linagliptin |
|---|---|
| Overall | 35.72 |
| eGFR<30 | 46.69 |
| eGFR 30 to 44 | 38.88 |
| eGFR 45 to 59 | 40.19 |
| eGFR 60 to 89 | 35.75 |
| eGFR ≥ 90 | 30.12 |
| eGFR not available | 30.37 |
Collected over Individual safety reporting is not applicable for this study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patients With Written Prescription for Initiating Linagliptin | — | — | — |
Patients with a written prescription for linagliptin were identified during an identification period starting on 01 January 2012 and ending on 30 September 2016.
| Age, Continuous(Years) | Patients With Written Prescription for Initiating Linagliptin |
|---|---|
| Mean | 64.30 ± 11.37 |
| Sex: Female, Male(Participants) | Patients With Written Prescription for Initiating Linagliptin |
|---|---|
| Female | 5603 |
| Male | 5398 |
| Ethnicity (NIH/OMB)(Participants) | Patients With Written Prescription for Initiating Linagliptin |
|---|---|
| Hispanic or Latino | 927 |
| Not Hispanic or Latino | 9550 |
| Unknown or Not Reported | 524 |
| Race (NIH/OMB)(Participants) | Patients With Written Prescription for Initiating Linagliptin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 241 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1455 |
| White | 8645 |
| More than one race | 0 |
| Unknown or Not Reported | 660 |
| Estimated glomerular filtration rate (eGFR)(participants) | Patients With Written Prescription for Initiating Linagliptin |
|---|---|
| <30 | 679 |
| 30 to 44 | 1646 |
| 45 to 59 | 1727 |
| 60 to 89 | 3256 |
| ≥ 90 | 2603 |
| eGFR not available | 1090 |
| Age categories(participants) | Patients With Written Prescription for Initiating Linagliptin |
|---|---|
| 40 to 54 years | 2325 |
| 55 to 64 years | 3332 |
| 65 to 74 years | 3077 |
| 75 years and above | 2267 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Feb 2018, 2 months.
Results were first posted in May 2019, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.